Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAMAR.
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing thrombus formation and propagation.
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
IV: Initial bolus of 5000 units followed by continuous infusion at 1300 units/hour, adjusted based on aPTT. Typical infusion range 1000-2000 units/hour.
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
None Documented
None Documented
30-60 minutes at therapeutic doses, dose-dependent (e.g., 100 U/kg yields t½ ~56 min; 400 U/kg yields ~152 min). At lower doses (e.g., 25 U/kg), t½ is ~30 min. Prolonged in hepatic or renal impairment.
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
Primarily renal; metabolism by hepatic and reticuloendothelial system desulfation yields uroheparin, which is excreted in urine. Unchanged heparin is also excreted renally, with elimination proportional to dose and molecular weight. Biliary/fecal excretion is negligible (<5%).
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Category A/B
Category C
Anticoagulant
Anticoagulant